Efficacy and Safety of Dupilumab Across Different Th2-Type-Mediated Diseases: A Real-Life Preliminary Experience
Background: Dupilumab, a fully human monoclonal antibody targeting the interleukin (IL)-4/IL-13 pathway, is able to dampen T helper (Th)2-mediated inflammation in several conditions characterized by this particular type of phlogosis. The aim of this study was to review the efficacy and safety of dup...
Saved in:
| Main Authors: | Ciro Romano, Domenico Cozzolino, Maria Elena Corona, Ernesto Aitella |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Biologics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2673-8449/5/1/3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Chronic pruritus: a narrative review
by: Paulo Ricardo Criado, et al.
Published: (2025-08-01) -
High Prevalence of Lash Collarettes in Patients with Atopic Dermatitis Treated with Dupilumab
by: Ilaria Trave, et al.
Published: (2025-08-01) -
Dupilumab for Chronic Rhinosinusitis with Primary Nasal Polyps: a Case Report and Literature Review
by: Deng M, et al.
Published: (2025-04-01) -
The Effect of Dupilumab on Growth Parameters in Pediatric Atopic Dermatitis Patients
by: Vincenzo Piccolo, et al.
Published: (2025-07-01) -
Dupilumab for the treatment of atopic dermatitis and alopecia areata with incidental improvement of trachyonychia
by: Dana H. Chung, BA, et al.
Published: (2025-09-01)